Press Releases

Year

Oct 09, 2018

Wave Life Sciences to Develop Programs in Rare, Genetic Eye Diseases

Research will focus on inherited retinal diseases associated with RHO, USH2A, ABCA4 and CEP290 Initial development candidate expected in H2 2019 CAMBRIDGE, Mass. , Oct. 09, 2018 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (NASDAQ: WVE), a biotechnology company focused on delivering

Sep 20, 2018

Wave Life Sciences to Present New Data on Its DMD Exon 53 Skipping Program and Discovery Platform at Upcoming Meetings

CAMBRIDGE, Mass. , Sept. 20, 2018 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (NASDAQ: WVE), a biotechnology company focused on delivering transformational therapies for patients with serious, genetically-defined diseases, today announced presentations at two upcoming meetings highlighting new data

Aug 16, 2018

Wave Life Sciences Receives US Orphan Drug and Rare Pediatric Disease Designations for WVE-210201

Investigational WVE-210201 in development for treatment of Duchenne muscular dystrophy patients amenable to exon 51 skipping CAMBRIDGE, Mass. , Aug. 16, 2018 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (NASDAQ: WVE), a biotechnology company focused on delivering transformational therapies for

Aug 09, 2018

Wave Life Sciences Reports Second Quarter 2018 Financial Results and Provides Business Update

CAMBRIDGE, Mass. , Aug. 09, 2018 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (NASDAQ: WVE), a biotechnology company focused on delivering transformational therapies for patients with serious, genetically-defined diseases, today announced financial results for the second quarter ended June 30, 2018

Jul 02, 2018

Wave Life Sciences Receives Positive Opinion for Orphan Drug Designation in the European Union for WVE-210201

Investigational WVE-210201 in development for treatment of Duchenne muscular dystrophy patients amenable to exon 51 skipping Patients currently enrolling in global Phase 1 clinical trial CAMBRIDGE, Mass. , July 02, 2018 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd.

Jun 25, 2018

Wave Life Sciences to Present at Parent Project Muscular Dystrophy Annual Conference

CAMBRIDGE, Mass. , June 25, 2018 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (NASDAQ:WVE), a biotechnology company focused on delivering transformational therapies for patients with serious, genetically-defined diseases, today announced that Paul Bolno , MD, MBA, President and Chief Executive

May 31, 2018

Wave Life Sciences to Present at the Jefferies 2018 Healthcare Conference

CAMBRIDGE, Mass. , May 31, 2018 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (NASDAQ:WVE), a biotechnology company focused on delivering transformational therapies for patients with serious, genetically-defined diseases, today announced that Paul Bolno , M.D., MBA, President and Chief Executive

May 09, 2018

Wave Life Sciences Reports First Quarter 2018 Financial Results and Provides Business Update

CAMBRIDGE, Mass. , May 09, 2018 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (NASDAQ:WVE), a biotechnology company focused on delivering transformational therapies for patients with serious, genetically-defined diseases, today announced financial results for the first quarter ended March 31, 2018 ,

May 07, 2018

Wave Life Sciences Highlights Progress on Hepatic Collaboration with Pfizer

With the designation of five targets, Pfizer nominates the maximum permitted under collaboration Collaboration moving toward candidate selection CAMBRIDGE, Mass. , May 07, 2018 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (NASDAQ:WVE), a biotechnology company focused on delivering transformational

Apr 17, 2018

Wave Life Sciences to Present Data on ALS and FTD Programs and on Huntington's Disease at the 2018 American Academy of Neurology Annual Meeting

CAMBRIDGE, Mass. , April 17, 2018 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (NASDAQ:WVE), a biotechnology company focused on delivering transformational therapies for patients with serious, genetically-defined diseases, will present key data on its amyotrophic lateral sclerosis (ALS) and